Navigation Links
Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
Date:9/24/2013

MOUNTAIN VIEW, Calif., Sept. 24, 2013 /PRNewswire/ -- Edison Pharmaceuticals announced today initiation of a phase 2 clinical trial titled "Therapeutic Trial of EPI-743 in Patients with Disorders of Energy Utilization or Oxidation-Reduction."

The trial is a double-blind, placebo-controlled crossover study in which subjects will receive either EPI-743 treatment or placebo for six months. They will then be crossed over to the other arm (treatment or placebo). Eligible subjects must possess defined or undefined genetic diagnoses that feature cellular oxidation/reduction or energy production defects.

Those children absent a genetic diagnosis will be recruited through the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP). The principle enrollment criterion stipulates that all subjects must have a neuromuscular disorder of suspected mitochondrial or metabolic etiology. All subjects will also be enrolled in a clinical trial studying the natural history of metabolic disorders. Prior to enrollment, patient cells will be analyzed in the laboratory to verify that the cells display biochemical abnormalities associated with mitochondrial disease and can be rescued by EPI-743. 

The primary endpoints in this study are improvement in disease severity and quality of life as measured by the Newcastle Pediatric Mitochondrial Disease Scale. Secondary outcome measures include neuromuscular function and disease-related biochemical markers. More information on study specifics is available on www.ClinicalTrials.gov.

Of the approximately 4 million children born each year in the United States, an estimated 4,000 will have a mitochondrial disease. However, this may be an underestimation of true disease prevalence, since many pediatric neuromuscular patients present with laboratory and clinical findings consistent with energy or mitoc
'/>"/>

SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Edison initiates coverage of Derma Sciences
2. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
3. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
4. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
5. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
6. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
10. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
11. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014 The global high ... marked by the ,Threat of Obsolescence, wherein technologies as ... rapidly. Pharmaceutical and biotechnology companies as well as academic ... content screening as a powerful research tool in drug ... fastest-growing segment in the high content screening market. In ...
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... provider for the medical industries, announced today the expansion of its ... New York City . genae Americas was incorporated in 2011. ... centered in one of the highest concentrations of medical innovation and ... , President at genae Americas. "The expansion of genae from ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3genae Opens Offices in New York City 2
... SILVER SPRING, Md., June 8, 2011 The Food and ... containing 80 mg of simvastatin — the highest approved dose ... of the risk of muscle injury. (Logo:   ... only be used by patients who have been taking it ...
... Merz Pharmaceuticals today announced that new data on ... from accessory (complexing) proteins, will be presented at ... of Parkinson,s Disease and Movement Disorders in Toronto, ... XEOMIN were safe and effective in the treatment ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Limit Use of 80 mg Simvastatin 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 2New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS) 3
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... roses -- literally -- may face an increased risk of dying ... study of over 3,000 older Americans, researchers found those who were ... more than three times as likely to die in the next ... In fact, anosmia -- the inability to distinguish odors -- was ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... the brain of a rat and a robot could ... QUT leading robotics researcher. , Dr Michael Milford ... study uses new computer algorithms to enable robots to ... "This is a very Frankenstein type of project," Dr ... thing together because we,re taking the eyes of a ...
(Date:10/1/2014)... people to keep their "eyes on the prize" may ... walking, staying focused on a specific target ahead can ... people walk there faster, psychology researchers have found. Their ... around the environment naturally, offers a new strategy to ... interested in exercise if physical activity seems daunting, which ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Predicting the future course of psychotic illness 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... the #1 co-ed,fitness club chain in the world, has ... has clubs operating in 46 states, Canada and Australia,serving ... other well-known fitness chains have recently scaled back their,expansion ... grow at,an impressive rate. In fact, in the past ...
... the eye region is also useful when trying to spot fatigue ... or less tired? Focus on the area around your eyes, a ... your age and level of fatigue. , When asked to ... looked at the eye region almost half the time, researchers ...
... profound impact on this country,s psyche. Eight years after ... events affected us. A number of studies have shown ... the terrorist attacks experienced heightened levels of stress and ... Research has also indicated that elevated levels of stress ...
... PARK, N.J. and NEW YORK, Feb. 2 HLTH Corporation ... subsidiary, WebMD Health Corp. (Nasdaq: WBMD ), today ... the three months ended December 31, 2008 at approximately 4:00 ... will host a conference call at 4:45 pm (ET) on ...
... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced ... Ph.D., M.B.A., to serve as president and chief executive officer. ... SCOLR Pharma board of directors since August 2007.Michael N. Taglich, ... very pleased that Dr. Morra has agreed to become SCOLR ...
... (TFAH) strongly supports President Obama,s call for a "complete ... outbreak of Salmonella tied to peanut butter ... Salmonella outbreaks in 2008 highlight the need ... released a comprehensive report, Fixing Food Safety: Protecting ...
Cached Medicine News:Health News:Anytime Fitness Opens 1,000th Club 2Health News:Anytime Fitness Opens 1,000th Club 3Health News:When Gauging Age, the Eyes Have It 2Health News:Driving under the influence (of stress): Regional effects of 9/11 attacks on driving 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 3Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 2Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 3
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
Lancets are the fine needles used with a lancing device to draw a blood sample for glucose testing. To make testing less painful, we developed lancets with extra-thin tips....
... The HEMOCHRON Jr. Signature Microcoagulation System ... bedside with just one drop (.015cc) of ... a portable, hand-held, battery-operated instrument, the HEMOCHRON ... capabilities and print (optional) both patient and ...
Inquire...
Medicine Products: